维得利珠单抗对炎症性肠病患者各系统影响的评价  

Evaluation of the effects of vedolizumab on different systems in patients with inflammatory bowel disease

作　　者：吕雪 王素敏[1] 马娜[1] 孙亚星 张哲 冯百岁[1] LYU Xue;WANG Su-min;MA Na;SUN Ya-xing;ZHANG Zhe;FENG Bai-sui(Department of Gastroenterology,The Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450014,China)

机构地区：[1]郑州大学第二附属医院消化内科,郑州450014

出　　处：《现代免疫学》2023年第5期429-433,共5页Current Immunology

基　　金：河南省科技攻关项目(212102310803);河南省医学科技攻关计划省部共建项目(SBGJ2018042);郑州大学前沿交叉研究专项项目(XKZDQY201906)。

摘　　要：维得利珠单抗是一种人源化的抗整合素α4β7单克隆抗体,在传统的认知中具有很高的肠道选择性,对炎症性肠病(inflammatory bowel disease,IBD)患者免疫系统的影响大部分都局限在肠道内。在人源化小鼠模型中,维得利珠单抗会阻断T细胞向炎症肠道组织的转运。因此,阻止T细胞转运到肠道,被认为是维得利珠单抗减轻肠道炎症的主要作用机制。然而,随着维得利珠单抗的广泛应用,其对除肠道以外机体其他系统的影响也时有报道,同时其作用的细胞亚群也不再局限于T细胞。维得利珠单抗对IBD患者肠道内的固有免疫细胞以及B细胞也有作用。此外,维得利珠单抗还可能用于治疗与肠内疾病活动相关的一些肠外表现(extra-intestinal manifestation,EIM),如周围关节炎和结节性红斑。该文总结了维得利珠单抗对IBD患者各系统的影响,以期帮助全面认识维得利珠单抗的作用机制。Vedolizumab is a humanized anti-integrinα4β7 monoclonal antibody believed to exhibit high intestinal specificity.Its impact on the immune system of patients with inflammatory bowel disease(IBD)is reported to be mostly restricted to the intestine.In a humanized mouse model,vedolizumab blocks T-cell trafficking to inflamed intestinal tissue.Therefore,preventing the transport of T cells to the gut is thought to be the main mechanism of vedolizumab in reducing intestinal inflammation.However,with the wide application of vedolizumab,its effects on systems other than the gut have been reported.In addition,its target cells are found not limited to T cells.Vedolizumab also acts on innate immune cells as well as B cells in the gut of IBD patients.Besides,vedolizumab may also be used to treat extra-intestinal manifestation(EIM)accompanied with enteral disease activity,such as peripheral arthritis and erythema nodosum.This review summarizes the effects of vedolizumab on different systems in IBD patients to help fully understand the mechanism of action of vedolizumab.

关 键 词：维得利珠单克隆抗体 炎症性肠病 固有免疫细胞 适应性免疫细胞 

分 类 号：R574.1[医药卫生—消化系统]